Acute Respiratory Distress Syndrome - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 84 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2014', provides an overview of the Acute Respiratory Distress Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Respiratory Distress Syndrome Overview 9
Therapeutics Development 10
Pipeline Products for Acute Respiratory Distress Syndrome - Overview 10
Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis 11
Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies 12
Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes 14
Acute Respiratory Distress Syndrome - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Acute Respiratory Distress Syndrome - Products under Development by Companies 19
Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes 20
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development 21
GlaxoSmithKline plc 21
Phylogica Limited 22
Altor BioScience Corporation 23
Therametrics holding AG 24
FirstString Research, Inc. 25
Faron Pharmaceuticals Oy 26
Clarassance, Inc. 27
Navigen Pharmaceuticals, Inc. 28
Serendex Pharmaceuticals A/S 29
Mallinckrodt plc 30
Acute Respiratory Distress Syndrome - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
dilmapimod - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ALT-836 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GSK-2586881 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
corticotropin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
perfluorocarbon - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GSK-2862277 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DasKloster-1000-04 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DasKloster-0141-01 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
drotrecogin alfa (activated) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
interferon beta-1a - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CG-367 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Drug to Inhibit Leptin Receptor for Respiratory Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Stromal Cell Therapy For Acute Respiratory Distress Syndrome - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Monoclonal Antibody to Inhibit uPA for ALI, Sepsis and Acute Respiratory Distress Syndrome - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PYC-35 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
S-1229 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
PYC-36 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PYC-38 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PYC-98 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Protein for ARDS - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Slit2N - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
sargramostim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Acute Respiratory Distress Syndrome - Recent Pipeline Updates 71
Acute Respiratory Distress Syndrome - Dormant Projects 75
Acute Respiratory Distress Syndrome - Discontinued Products 76
Acute Respiratory Distress Syndrome - Product Development Milestones 77
Featured News & Press Releases 77
Oct 22, 2013: Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome 77
Jun 03, 2013: CVie Therapeutics Submits Application For Phase II Clinical Study Of Istaroxime Injection In China 77
Nov 29, 2012: Faron Pharma Receives €6m Grant From European Commission For Traumakine Program 78
Sep 19, 2012: Unigene And Tarix Pharma Announce Completion Of Feasibility Study Of TXA127 78
May 21, 2012: Faron Pharma Announces Presentation Of New data From ALI/ARDS FPCLI001 Study At 2012 AmericanThoracic Society Meeting 79
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries 80
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease 80
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI 81
Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201 81
Jan 17, 2011: Rentschler And Faron Pharma Sign Manufacturing And Supply Agreement For Traumakine 82
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables
Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2014 10
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline plc, H2 2014 21
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2014 22
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2014 23
Acute Respiratory Distress Syndrome - Pipeline by Therametrics holding AG, H2 2014 24
Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2014 25
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2014 26
Acute Respiratory Distress Syndrome - Pipeline by Clarassance, Inc., H2 2014 27
Acute Respiratory Distress Syndrome - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 28
Acute Respiratory Distress Syndrome - Pipeline by Serendex Pharmaceuticals A/S, H2 2014 29
Acute Respiratory Distress Syndrome - Pipeline by Mallinckrodt plc, H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 39
Number of Products by Stage and Molecule Type, H2 2014 41
Acute Respiratory Distress Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 71
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2014 75
Acute Respiratory Distress Syndrome - Discontinued Products, H2 2014 76